文献速递消化系统肿瘤

AXL预测RAS野生型转移性结直肠癌不良生存及抗EGFR治疗耐药

AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer.
PubMed 文献 · Eur J Cancer · 2020-08-17

该回顾性研究在307例mCRC患者中评估AXL免疫组化表达,其中136例RAS野生型接受一线抗EGFR治疗,171例RAS突变型接受抗血管生成治疗。AXL阳性与总体人群及RAS野生型患者更差生存相关,且RAS野生型中AXL阳性者PFS更短。临床前及转化数据支持AXL参与原发性和获得性抗EGFR耐药。

要点

  • AXL阳性与mCRC总体人群和RAS野生型患者更差生存相关。
  • RAS野生型mCRC中AXL阳性者接受抗EGFR治疗的PFS更短。
  • 临床前证据支持AXL参与抗EGFR原发性和获得性耐药。

核心结论

  • AXL是mCRC不良预后标志物,临床和临床前证据一致提示其参与RAS野生型患者抗EGFR原发性和获得性耐药。

研究设计与样本

  • 回顾性免疫组化评估307例mCRC患者AXL表达,其中RAS野生型136例接受一线抗EGFR治疗,RAS突变型171例接受抗血管生成方案。
  • 临床前使用人RAS野生型结直肠癌细胞系和异种移植模型,并在基线和抗EGFR进展时评估AXL RNA水平,另分析GSE5851数据集。

主要发现

  • 307例中55例肿瘤组织表达AXL,总体人群AXL阳性者生存23.7个月,AXL阴性者30.8个月,HR 1.455,P=0.032。
  • RAS野生型患者中AXL阳性者生存23.0个月,AXL阴性者35.8个月,HR 1.780,P=0.032。
  • RAS野生型队列中AXL阳性者PFS为6.2个月,AXL阴性者12.1个月,HR 1.796,P=0.013。
  • 一例抗EGFR治疗后患者的三维培养呈AXL阳性,显示对抗EGFR药物耐药且对AXL抑制敏感。
  • 结直肠癌细胞系转染AXL诱导AXL过表达和EGFR blockade耐药;西妥昔单抗进展时2/10 SW48异种移植小鼠显示AXL表达,5/7患者抗EGFR治疗后AXL RNA水平升高。

关键数值与推荐

  • GSE5851数据集中,KRAS外显子2野生型化疗难治患者AXL RNA水平较高与西妥昔单抗PFS更差相关。

临床怎么用

  • AXL免疫组化可能用于RAS野生型mCRC接受抗EGFR治疗患者的预后分层和耐药风险提示。
  • AXL阳性提示对抗EGFR药物原发或获得性耐药,AXL抑制可能是潜在策略。

局限性

  • AXL为回顾性免疫组化评估,样本量有限。
  • 临床前和转化数据来自细胞系、异种移植模型及小样本患者,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: RAS mutations are the only validated biomarkers in metastatic colorectal cancer (mCRC) for anti-epidermal growth factor receptor (EGFR) therapy. Limited clinical information is available on AXL expression, marker of epithelial to mesenchymal transition, in mCRC. METHODS: AXL was retrospectively assessed by immunohistochemistry in 307 patients. RAS wild-type (WT) patients (N = 136) received first-line anti-EGFR-based therapy; RAS mutant patients (N = 171) received anti-angiogenic-based regimens. Preclinical experiments were performed using human RAS WT CRC cell lines and xenograft models. AXL RNA levels were assessed in a cohort of patients with available samples at baseline and at progression to anti-EGFR treatment and in the GSE5851 dataset. RESULTS: AXL was expressed in 55/307 tumour tissues, correlating with worse survival in the overall population (AXL-positive, 23.7 months; AXL-negative, 30.8 months; HR, 1.455, P = 0.032) and in RAS WT patients (AXL-positive, 23.0 months; AXL-negative, 35.8 months; HR,1.780, P = 0.032). Progression-free survival (PFS) in the RAS WT cohort was shorter in the AXL-positive cohort (6.2 months versus 12.1 months; HR, 1.796, P = 0.013). Three-dimensional cultures obtained from a patient following anti-EGFR therapy resulted AXL-positive, showing resistance to anti-EGFR drugs and sensitivity to AXL inhibition. AXL transfection in CRC cell lines induced AXL overexpression and resistance to the EGFR blockade. At progression to cetuximab, 2/10 SW48-tumour xenograft mice showed AXL expression. Consistently, AXL RNA levels increased in 5/7 patients following anti-EGFR therapy. Moreover, in the GSE5851 dataset higher AXL RNA levels correlated with worse PFS with cetuximab in KRAS-exon2 WT chemorefractory patients. CONCLUSIONS: AXL is a marker of poor prognosis in mCRC with consistent clinical and preclinical evidences of involvement in primary and acquired resistance to anti-EGFR drugs in RAS WT patients.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Cardone C, Blauensteiner B, Moreno-Viedma V, et al. AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. Eur J Cancer. 2020. PMID: 32818762. doi:10.1016/j.ejca.2020.07.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。